Literature DB >> 31392646

Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis.

J Gootee1, N Sioda2, S Aurit3, C Curtin2, P Silberstein4.   

Abstract

BACKGROUND: Leiomyosarcoma (LMS) is an aggressive, malignant mesenchymal tumor with characteristic smooth muscle lineage accounting for 10-20% of all soft tissue tumors. The goal of this study is to determine the impact of prognostic factors on leiomyosarcoma survival irrespective of primary anatomical site.
METHODS: There were a total of 7154 patients with primary leiomyosarcoma identified and analyzed from the National Cancer Database. Descriptive statistics, median survival, and 5- and 10-year survival probabilities were calculated along with a Cox proportional hazard model to determine independent prognostic factors.
RESULTS: In this study, females comprised 68.3% of the cohort with a median age of 58 years. The most common primary anatomical sites were the extremities followed by female reproductive organs, abdomen, pelvis, thorax or lung, and head or neck. Tumors localized in the female reproductive organs had the worst survival (5-year survival probability: 45.3%), while tumors localized in the extremities had the best survival outcomes (5-year survival probability: 73.4%). Surgery with adjuvant radiation yielded better outcomes compared to surgery alone (HR 0.82, 95% CI 0.74-0.91). Microscopic and macroscopic margins resulted in a 32% and a 134% increased risk in mortality, respectively, when compared to negative surgical margins (p < 0.0001).
CONCLUSION: This study showed a significantly higher risk of mortality associated with older patients, tumors localized to the female reproductive organs, African American patients, higher tumor stage, increased Charlson/Deyo scores, tumors treated with surgery alone without adjuvant radiation, and tumors with positive microscopic, macroscopic, or indeterminate surgical margins.

Entities:  

Keywords:  Leiomyosarcoma; National cancer database; Primary anatomical site; Surgical margins; Survivorship

Year:  2019        PMID: 31392646     DOI: 10.1007/s12094-019-02196-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

1.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

Review 2.  Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants.

Authors:  Andrew J Bathan; Anastasia Constantinidou; Seth M Pollack; Robin L Jones
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

3.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Authors:  Kristelle Lusby; Kari Brewer Savannah; Elizabeth G Demicco; Yiqun Zhang; Markus Ph Ghadimi; Eric D Young; Chiara Colombo; Ryan Lam; Tugce E Dogan; Jason L Hornick; Alexander J Lazar; Kelly K Hunt; Matthew L Anderson; Chad J Creighton; Dina Lev; Raphael E Pollock
Journal:  Ann Surg Oncol       Date:  2013-01-20       Impact factor: 5.344

5.  Predictors of survival and recurrence in primary leiomyosarcoma.

Authors:  Rebecca A Gladdy; Li-Xuan Qin; Nicole Moraco; Narasimhan P Agaram; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2013-01-25       Impact factor: 5.344

6.  The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma.

Authors:  Jason D Wright; Venkatraman E Seshan; Monjri Shah; Peter B Schiff; William M Burke; Carmel J Cohen; Thomas J Herzog
Journal:  Am J Obstet Gynecol       Date:  2008-06-03       Impact factor: 8.661

7.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

Authors:  N S Reed; C Mangioni; H Malmström; G Scarfone; A Poveda; S Pecorelli; S Tateo; M Franchi; J J Jobsen; C Coens; I Teodorovic; I Vergote; J B Vermorken
Journal:  Eur J Cancer       Date:  2008-04-02       Impact factor: 9.162

Review 8.  Uterine leiomyosarcoma: A review of the literature and update on management options.

Authors:  Maureen E Roberts; Jason T Aynardi; Christina S Chu
Journal:  Gynecol Oncol       Date:  2018-09-21       Impact factor: 5.482

9.  Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.

Authors:  Zhijie Wang; Naiyi Shi; Aung Naing; Filip Janku; Vivek Subbiah; Dejka M Araujo; Shreyaskumar R Patel; Joseph A Ludwig; Lois M Ramondetta; Charles F Levenback; Pedro T Ramirez; Sarina A Piha-Paul; David Hong; Daniel D Karp; Apostolia M Tsimberidou; Funda Meric-Bernstam; Siqing Fu
Journal:  Cancer Med       Date:  2016-11-23       Impact factor: 4.452

10.  Paratesticular Leiomyosarcoma: A Case Report and Review of the Literature.

Authors:  Joana Alfarelos; Gustavo Gomes; Francisco Campos; Mário Matias; Amaral Canelas; Matilde Gonçalves
Journal:  Urol Case Rep       Date:  2017-01-07
View more
  2 in total

1.  Conjunctival leiomyosarcoma.

Authors:  Aluisio Rosa Gameiro Filho; Ana Marisa Pires Castello Branco; Moacyr Pezati Rigueiro; Melina Correia Morales; Rubens N Belfort
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-11

2.  Bone Metastases in Patients with Leiomyosarcoma: A Retrospective Analysis of Survival and Surgical Management.

Authors:  Christa L LiBrizzi; Ashish Vankara; Christian F Meyer; Adam S Levin; Carol D Morris
Journal:  Sarcoma       Date:  2022-05-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.